Taiwan
The Development Center for Biotechnology (DCB) of Taiwan, founded in 1984, is a non-profit organization supported by the Department of Industrial Technology, Ministry of Economic Affairs. DCB’s objective is to advance Taiwan's biotech-pharma industry by building infrastructure, developing key technologies, and training talented workforces in coordination with government, industry, and academic institutions. In line with Taiwan's current biotech-pharma development policy, which emphasizes value-addition and knowledge-basis, DCB positions itself as a "Preclinical Value-Adding R&D Center for Biopharmaceuticals". This role is to be fulfilled by devoting concerted R&D efforts on protein, small molecule and botanical drug leads in the preclinical stage of development and setting top priorities for attaining Investigational New Drug approvals by domestic and foreign regulatory agencies.
The division of Industrial Promotion provides industrial information, services, facilitates technology transfer, and overall fosters international partnerships for commercialization. Many of these functions are performed in conjunction with outpost team members managing other government-sponsored programs, such as the Biotechnology and Pharmaceutical Industries Program Office (BPIPO; commissioned by the Industrial Development Bureau, MOEA), and the Nankang Biotech Incubation Center (NBIC; commissioned by the Small and Medium Enterprise Administration, MOEA).
DCB is dedicated to R&D in botanic drug products, pharmaceuticals, biologics, animal pharmacology, and innovative and explorative research. DCB also establishes itself as a licensing technology platform. At present, the therapeutic areas for drug development include cancer, diabetes, as well as infectious, inflammatory, and cardiovascular diseases.
DCB operates in the Biotechnology, Industrial, and Pharmaceutical industries, positioning itself as a valuable player in Taiwan's biotech-pharma sector, with a focus on preclinical R&D and commercialization support. With its longstanding presence and support from the government, DCB presents potential opportunities for investment and collaboration in the dynamic biopharmaceutical space.
